Acute kidney injury in hematopoietic cell transplantation

Seminars in Nephrology

Volumn 30, Issue 6, 2010, Pages 615-626

  Kogon, Amy ^a   Hingorani, Sangeeta ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Acute kidney injury; Albuminuria; Hematopoietic cell transplant; Risk factors

Indexed keywords

ACICLOVIR; ALBUMIN; ALEMTUZUMAB; ALTEPLASE; AMPHOTERICIN; AMPHOTERICIN B; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEFIBROTIDE; FLUCONAZOLE; FLUDARABINE; FOSCARNET; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; TOBRAMYCIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ALBUMINURIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOTRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; BREAST CANCER; CANDIDIASIS; CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; COMORBIDITY; CYTOMEGALOVIRUS INFECTION; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; EARLY INTERVENTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL TRANSPLANTATION; HLA MATCHING; HUMAN; KIDNEY INJURY; KIDNEY TUBULE DAMAGE; LIVER DISEASE; LIVER VEIN OBSTRUCTION; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MYELOABLATIVE CONDITIONING; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PHOTOTHERAPY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; PUVA; REDUCED INTENSITY CONDITIONING; RENAL PROTECTION; SEPSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; VIREMIA; VIRUS INFECTION; WHOLE BODY RADIATION;

ACUTE KIDNEY INJURY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MYELOABLATIVE AGONISTS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 78649938801     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2010.09.009     Document Type: Article

References (47)

1. Kersting S., Koomans H.A., Hene R.J., Verdonck L.F. Acute renal failure after allogeneic myeloablative stem cell transplantation: retrospective analysis of incidence, risk factors and survival. Bone Marrow Transplant 2007, 39:359-365.
2. Hingorani S.R., Guthrie K., Batchelder A., Schoch G., Aboulhosn N., Manchion J., et al. Acute renal failure after myeloablative hematopoietic cell transplant: incidence and risk factors. Kidney Int 2005, 67:272-277.
3. Kersting S., Dorp S.V., Theobald M., Verdonck L.F. Acute renal failure after nonmyeloablative stem cell transplantation in adults. Biol Blood Marrow Transplant 2008, 14:125-131.
4. Parikh C.R., Schrier R.W., Storer B., Diaconescu R., Sorror M.L., Maris M.B., et al. Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. Am J Kidney Dis 2005, 45:502-509.
5. Zager R.A., O'Quigley J., Zager B.K., Alpers C.E., Shulman H.M., Gamelin L.M., et al. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis 1989, 13:210-216.
6. Lopes J.A., Jorge S., Silva S., de Almeida E., Abreu F., Martins C., et al. Acute renal failure following myeloablative autologous and allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2006, 38:707.
7. Lopes J.A., Goncalves S., Jorge S., Raimundo M., Resende L., Lourenco F., et al. Contemporary analysis of the influence of acute kidney injury after reduced intensity conditioning haematopoietic cell transplantation on long-term survival. Bone Marrow Transplant 2008, 42:619-626.
8. Parikh C.R., McSweeney P.A., Korular D., Ecder T., Merouani A., Taylor J., et al. Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int 2002, 62:566-573.
9. Parikh C.R., Sandmaier B.M., Storb R.F., Blume K.G., Sahebi F., Maloney D.G., et al. Acute renal failure after nonmyeloablative hematopoietic cell transplantation. J Am Soc Nephrol 2004, 15:1868-1876.
10. Merouani A., Shpall E.J., Jones R.B., Archer P.G., Schrier R.W. Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. Kidney Int 1996, 50:1026-1031.
11. Schrier R.W., Parikh C.R. Comparison of renal injury in myeloablative autologous, myeloablative allogeneic and non-myeloablative allogeneic haematopoietic cell transplantation. Nephrol Dial Transplant 2005, 20:678-683.
12. Caliskan Y., Besisik S.K., Sargin D., Ecder T. Early renal injury after myeloablative allogeneic and autologous hematopoietic cell transplantation. Bone Marrow Transplant 2006, 38:141-147.
13. Hahn T., Rondeau C., Shaukat A., Jupudy V., Miller A., Alam A.R., et al. Acute renal failure requiring dialysis after allogeneic blood and marrow transplantation identifies very poor prognosis patients. Bone Marrow Transplant 2003, 32:405-410.
14. Parimon T., Au D.H., Martin P.J., Chien J.W. A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006, 144:407-414.
15. Carella A.M., Champlin R., Slavin S., McSweeney P., Storb R. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant 2000, 25:345-350.
16. Chao N.J. Pharmacology and use of immunosuppressive agents after hematopoietic cell transplantation. Hematopoietic cell transplantation 1999, 176-185. Blackwell Science, Malden. 2nd ed. E.D. Thomas, K.G. Blume, S.J. Forman (Eds.).
17. Leather H.L., Wingard J.R. Bacterial infections. Thomas' hematopoietic cell transplant 2009, 1325-1345. Wiley-Blackwell, Malden. 4th ed. F.R. Appelbaum, K.G. Blume, S.J. Forman, R.S. Negrin (Eds.).
18. Zaia J.A. Cytomegalovirus infections. Thomas' hematopoietic cell transplantation 2009, 1367-1381. Wiley-Blackwell, Malden. 4th ed. F.R. Appelbaum, K.G. Blume, S.J. Forman, R.S. Negrin (Eds.).
19. Ito J. Herpes simplex virus infections. Thomas' hematopoietic cell transplantation 2009, 1382-1387. Wiley-Blackwell, Malden. 4th ed. F.R. Appelbaum, K.G. Blume, S.J. Forman, R.S. Negrin (Eds.).
20. Vogelsang G., Pavletic S. Chronic graft versus host disease: interdisciplinary management 2009, University Press, New York: Cambridge.
21. Parikh C.R., Coca S.G. Acute renal failure in hematopoietic cell transplantation. Kidney Int 2006, 69:430-435.
22. Lopes J.A., Jorge S., Silva S., de Almeida E., Abreu F., Martins C., et al. An assessment of the RIFLE criteria for acute renal failure following myeloablative autologous and allogeneic haematopoietic cell transplantation. Bone Marrow Transplant 2006, 38:395.
23. Zager R.A., Andoh T., Bennett W.M. Renal cholesterol accumulation: a durable response after acute and subacute renal insults. Am J Pathol 2001, 159:743-752.
24. Zager R.A., Shah V.O., Shah H.V., Zager P.G., Johnson A.C., Hanson S. The mevalonate pathway during acute tubular injury: selected determinants and consequences. Am J Pathol 2002, 161:681-692.
25. Fadia A., Casserly L.F., Sanchorawala V., Seldin D.C., Wright D.G., Skinner M., et al. Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis. Kidney Int 2003, 63:1868-1873.
26. Pinana J.L., Valcarcel D., Martino R., Barba P., Moreno E., Sureda A., et al. Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience. Biol Blood Marrow Transplant 2009, 15:21-29.
27. Linck D., Basara N., Tran V., Vucinic V., Hermann S., Hoelzer D., et al. Peracute onset of severe tumor lysis syndrome immediately after 4 Gy fractionated TBI as part of reduced intensity preparative regimen in a patient with T-ALL with high tumor burden. Bone Marrow Transplant 2003, 31:935-937.
28. Deliliers G.L., Annaloro C. Hyperuricemia and bone marrow transplantation. Contrib Nephrol 2005, 147:105-114.
29. Mughal T.I., Ejaz A.A., Foringer J.R., Coiffier B. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev 2010, 36:164-176.
30. Schrier R.W., Wang W. Acute renal failure and sepsis. N Engl J Med 2004, 351:159-169.
31. Olsen K.M., Rudis M.I., Rebuck J.A., Hara J., Gelmont D., Mehdian R., et al. Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity. Crit Care Med 2004, 32:1678-1682.
32. Woo M., Przepiorka D., Ippoliti C., Warkentin D., Khouri I., Fritsche H., et al. Toxicities of tacrolimus and cyclosporin A after allogeneic blood stem cell transplantation. Bone Marrow Transplant 1997, 20:1095-1098.
33. DeLeve L.D., Shulman H.M., McDonald G.B. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002, 22:27-42.
34. Fink J.C., Cooper M.A., Burkhart K.M., McDonald G.B., Zager R.A. Marked enzymuria after bone marrow transplantation: a correlate of veno-occlusive disease-induced "hepatorenal syndrome.". J Am Soc Nephrol 1995, 6:1655-1660.
35. McDonald G. Hepatobiliary complications of hematopoietic cell transplant, 40 years on. Hepatology 2010, 51:1450-1460.
36. Richardson P.G., Soiffer R.J., Antin J.H., Uno H., Jin Z., Kurtzberg J., et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multi-organ failure post stem cell transplantation: a multi-center, randomized, dose-finding trial. Biol Blood Marrow Transplant 2010, 16:1005-1017.
37. Hingorani S., Seidel K., Aneja T., Schoch G., Lindner A., McDonald G. Albuminuria in hematopoietic cell transplant (HCT) patients: prevalence and risk factors. J Am Soc Nephrol 2006, 17:405A.
38. Nakamae H., Yamane T., Hasegawa T., Nakamae M., Terada Y., Hagihara K., et al. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. Am J Hematol 2006, 81:525-531.
39. Daly A.S., Hasegawa W.S., Lipton J.H., Messner H.A., Kiss T.L. Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver. Transfus Apher Sci 2002, 27:3-12.
40. Holler E., Kolb H.J., Hiller E., Mraz W., Lehmacher W., Gleixner B., et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood 1989, 73:2018-2024.
41. Roy V., Rizvi M.A., Vesely S.K., George J.N. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant 2001, 27:641-646.
42. Changsirikulchai S., Myerson D., Guthrie K.A., McDonald G.B., Alpers C.E., Hingorani S.R. Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis. Clin J Am Soc Nephrol 2009, 4:345-353.
43. van der Plas R.M., Schiphorst M.E., Huizinga E.G., Hene R.J., Verdonck L.F., Sixma J.J., et al. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 1999, 93:3798-3802.
44. Hingorani S.R., Seidel K., Lindner A., Aneja T., Schoch G., McDonald G. Albuminuria in hematopoietic cell transplantation patients: prevalence, clinical associations, and impact on survival. Biol Blood Marrow Transplant 2008, 14:1365-1372.
45. Star R.A. Treatment of acute renal failure. Kidney Int 1998, 54:1817-1831.
46. Parikh C.R., McSweeney P., Schrier R.W. Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant. Kidney Int 2005, 67:1999-2005.
47. Parikh C.R., Yarlagadda S.G., Storer B., Sorror M., Storb R., Sandmaier B. Impact of acute kidney injury on long-term mortality after nonmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008, 14:309-315.